School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
School of Basic Medical Science, Yunnan University of Chinese Medicine, Yunnan Kunming 650500, China.
Biomed Res Int. 2021 Mar 10;2021:6630598. doi: 10.1155/2021/6630598. eCollection 2021.
Although increasing evidence reveals the efficacy of traditional Chinese medicine (TCM) and its safety on Tourette Syndrome (TS) patients, whether TCM is indeed improving TS remains unclear. The purpose of the current study is to perform a meta-analysis to evaluate the efficacy and safety of TCM on treating TS patients.
An elaborate search strategy was conducted based on several databases including Medline, Embase, Cochrane, Web of Science, CINAHL, CBM, VIP, CNKI, and Wanfang Data in order to identify the relevant randomized controlled trials (RCTs) from their inception to as late as May 1st, 2020. General information and data needing analysis were extracted simultaneously for the necessity of various analyses such as descriptive analysis and metaquantitative analysis.
Forty-seven trials with 5437 TS patients in total were eventually included according to our criteria. All trials were conducted in China, and the publication years ranged from 2004 to 2017. In terms of clinical efficacy, clinical symptoms of patients with TCM were more likely to be improved compared with the control group (odds ratio, OR = -1.29, 95% confidence interval, CI: -2.54 to -0.06, = 0.00%). As to the outcome of recurrence rate, the pooled results revealed that the TCM group was more inclined to stabilize the recurrence (OR = 0.44, 95% CI: 0.24 to 0.78, = 0.00%). Similar results were observed in adverse reaction (OR = 0.32, 95% CI: 0.24 to 0.43, = 32.90%).
The results of our study recommend applying TCM to treat TS patients for better efficacy and safety. Results need to be interpreted cautiously due to certain limitations in our study.
虽然越来越多的证据表明中药(TCM)对抽动秽语综合征(TS)患者有效且安全,但 TCM 是否确实改善 TS 仍不清楚。本研究的目的是进行荟萃分析,以评估 TCM 治疗 TS 患者的疗效和安全性。
根据 Medline、Embase、Cochrane、Web of Science、CINAHL、CBM、VIP、CNKI 和万方数据等多个数据库,制定了详细的搜索策略,以从研究开始到 2020 年 5 月 1 日为止,确定相关的随机对照试验(RCT)。同时提取一般信息和需要分析的数据,以便进行描述性分析和荟萃定量分析等各种分析。
根据我们的标准,最终纳入了 47 项试验,共 5437 例 TS 患者。所有试验均在中国进行,发表年份为 2004 年至 2017 年。在临床疗效方面,与对照组相比,TCM 组患者的临床症状更有可能得到改善(比值比,OR = -1.29,95%置信区间,CI:-2.54 至-0.06, = 0.00%)。至于复发率的结果,汇总结果表明 TCM 组更倾向于稳定复发(OR = 0.44,95%CI:0.24 至 0.78, = 0.00%)。不良反应的结果也相似(OR = 0.32,95%CI:0.24 至 0.43, = 32.90%)。
我们的研究结果建议将 TCM 应用于治疗 TS 患者,以获得更好的疗效和安全性。由于我们研究中的某些局限性,结果需要谨慎解释。